Lonza Group Ltd is expanding its cell therapy business with the construction of a new facility in Singapore.

This new facility will broaden the global presence and consolidate Lonza's leading position in the area of cell therapy production. The new facility will be located adjacent to Lonza's large-scale mammalian manufacturing facility at Tuas Biomedical Park. The total investment for the first phase will be approximately CHF 30 million.

Cellular-based therapeutics promise to address many unmet medical